Patients with hypertension, particularly those with diabetes mellitus, are at heightened risk for cardiovascular and renal disease. Accumulated evidence indicates that the majority of hypertensive patients at high risk will require more than one antihypertensive agent to reach their blood pressure (BP) target. A reasonable strategy is to use agents with complementary mechanisms of action to enhance BP-lowering efficacy and prevent target organ damage. In experimental models, the combination of a calcium channel blocker (CCB) with an agent that blocks the renin-angiotensin system (RAS), an angiotensinconverting enzyme (ACE) inhibitor or angiotensin receptor blocker, improves measures of endothelial function, inflammation, ventricular remodelling and renal function to a greater degree than these classes given as monotherapy. In clinical trials, calcium channel/RAS blockade combination therapy has been shown to provide greater BP reductions and improve renal function in patients with diabetic and nondiabetic renal disease earlier and to a greater extent than monotherapy. In addition, dual calcium channel/RAS blockade increases arterial compliance, arterial distensibility and flow-mediated vasodilation. Expanding upon extensive research on the benefits of calcium channel blockade and RAS blockade for the prevention of vascular events and preclinical and clinical trial evidence suggests added effects of combination therapy by targeting the underlying mechanisms of hypertensive vascular disease.
Introduction
Hypertension is the most common primary diagnosis in the United States and, as the population ages, will likely remain so. Despite concerted efforts, blood pressure (BP) remains poorly controlled, particularly in high-risk populations. The most recent age-adjusted estimates show that BP control increased to 64% in treated patients, but was only 33% in hypertensive patients overall, 1 based on targets for patients with uncomplicated hypertension (o140/90 mm Hg) established by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). 2 Despite treatment with antihypertensive therapy, only 33% of patients with diabetes mellitus reach the more stringent goal of o130/80 mm Hg, recommended for patients with diabetes or renal insufficiency. Although available antihypertensive agents are effective, most patients at high cardiovascular risk require X2 agents to achieve their BP goal; [2] [3] [4] persons with diabetes may require X3 drugs to reach the lower BP targets. 5 Therefore, JNC 7 and the European Society of Hypertension recommend considering initiation of treatment with combination therapy when patients require greater than a 20/10-mm Hg reduction to reach target BP levels. 2, 6 The relationship between BP and cardiovascular disease is continuous and graded, such that persons with the highest BP are at the highest risk of stroke, myocardial infarction, heart failure and kidney disease. 2 In recognition of the increased risk associated with moderately elevated BP, JNC 7 established a prehypertension category of systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg. 2, 7 Expanding on the concept of increased risk at all BP levels, the Hypertension Writing Group proposed that the definition and classification of hypertension be modified to include cardiovascular risk factors, early disease markers and evidence of target organ damage. 8 Their schema recognizes the progressive nature of hypertension, its complex aetiology, the potential for adverse cardiovascular outcomes before a discrete elevated BP level is observed and the need for early intervention in patients at risk.
Extensive evidence demonstrates conclusively that lowering BP with antihypertensive therapy reduces the risk of cardiovascular events. [9] [10] [11] However, considerable controversy surrounds the relative benefits of BP lowering per se versus ancillary effects of different classes of antihypertensive agents on the underlying mechanisms of vascular disease. 12 Nevertheless, evidence suggests differential benefits of antihypertensive classes for specific clinical outcomes, [12] [13] [14] [15] [16] [17] such that treatment guidelines recommend the selection of antihypertensive therapy based on the individual patient's global risk. 2, 5, 18 Since most patients at high risk require combination therapy to achieve BP goals, selecting agents with complementary mechanisms of action has the greatest potential to accomplish the major goal of treatment: preventing end-organ damage. Two of the most robust means for facilitating BP control with a rennin-angiotensin system (RAS) blocker are the addition of either a thiazide diuretic or a calcium channel blocker (CCB). There are pros and cons with each type of combination approach. This article reviews experimental and clinical evidence suggesting the additive effects of dual calcium channel/ RAS blockade for reducing BP and preventing cardiovascular and renal disease events.
To identify recent studies evaluating the effect of combination therapy on intermediate or clinical outcomes, a Medline search was conducted for articles published between January 2002 and April 2007 using the following search terms: angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; calcium channel blocker; combination therapy; antihypertensive; cardiovascular; and renal. The focus was narrowed to studies of the most commonly prescribed dihydropyridine CCB, amlodipine.
RAS blockade
The RAS mediates adaptive and maladaptive responses to cell and tissue injury, and thereby plays a central role in the pathophysiology of cardiovascular and renal disease through its main effector, the potent vasoconstrictor angiotensin II. 19 The angiotensin II type 1 (AT 1 ) receptor mediates numerous deleterious effects of angiotensin II, including vasoconstriction, sympathetic nervous system activation, smooth muscle cell growth and proliferation, vascular inflammation, generation of reactive oxygen species and endothelial dysfunction ( Figure 1 ). 20 Normal endothelial cells produce the vasodilators nitric oxide (NO) and prostacyclin, as well as the antithrombogenic tissue plasminogen activator (t-PA). Endothelial cells also produce ACE, which converts angiotensin I to angiotensin II. Angiotensin II opposes the vasodilating effects of NO, stimulates the production of endothelin-1 (another vasoconstrictor), 21 adhesion factors and plasminogen activator inhibitor-1 (PAI-1), which promote coagulability and risk of thrombosis, 19, 22 and increases vascular stiffness. 23 Normally, NO downregulates endothelial synthesis of ACE and thereby reduces angiotensin II activity. Endothelial dysfunction and impaired NO production, as a result of hypertension and other 24, 25 ARBs selectively antagonize all AT 1 receptor effects and stimulate AT 2 receptors, which may counteract negative AT 1 effects. 20 RAS blockade has been shown in clinical studies and experimental models to improve endothelial function 15, [26] [27] [28] [29] [30] [31] [32] [33] and fibrinolytic activity, 22, [34] [35] [36] and to decrease vascular inflammation, [37] [38] [39] [40] platelet activity 41, 42 and oxidative stress. 43, 44 In clinical trials, RAS blockade has been shown to reduce the risk of cardiovascular events and mortality, [45] [46] [47] and demonstrates benefit for patients with left ventricular hypertrophy, 48 stroke, 49 heart failure 50,51 and nondiabetic 16 and diabetic renal disease. [52] [53] [54] [55] [56] [57] Based on extensive evidence, an agent that blocks the RAS is considered an essential component of treatment for patients with hypertension and diabetes or chronic kidney disease. 5, 18 According to JNC 7 guidelines, 2 compelling indications for the use of RAS blockade in patients with hypertension include heart failure, post-myocardial infarction, high coronary disease risk, diabetes mellitus, chronic kidney disease and recurrent stroke prevention.
Calcium channel blockade
Calcium influx through L-type calcium channels causes vasoconstriction by raising intracellular calcium concentrations in vascular smooth muscle cells. CCBs inhibit the flow of calcium ions into vascular smooth muscle, thereby dilating large resistance arteries. In addition to BP-lowering effects, CCBs promote fibrinolysis by increasing the activity of t-PA, 22 decrease inflammatory markers after cardiac ischaemia, 58 inhibit proliferation of vascular smooth muscle cells and extracellular matrix formation, 59, 60 and inhibit cytokine-induced apoptosis of endothelial cells. 61 CCBs, including amlodipine also improve endothelial function by stimulating the release of NO and restoring the balance between angiotensin II and NO, 21, 24 even though endothelial cells do not contain L-type calcium channels. 62 Instead, the effect of amlodipine on endothelial NO appears to occur via local kinin production and a bradykinin receptor-mediated mechanism. 62 CCBs are important BP-lowering agents that are effective regardless of age, gender, ethnicity, salt intake or nonsteroidal anti-inflammatory drug use. [63] [64] [65] The benefit of amlodipine in patients with established coronary artery disease has been suggested in several clinical trials. 66 ,67 JNC 7 recommends CCBs for use in isolated systolic hypertension, with the exception of heart failure associated with systolic dysfunction, in which some CCBs have been associated with increased risk. 2, 4 Results of meta-analyses suggest the benefit of CCBs for stroke reduction, 14, 17 which may be related to the robust BP reductions associated with this antihypertensive class. JNC 7 also identifies diabetes and high coronary disease risk as compelling indications for the use of CCBs. 2 
Dual calcium channel/RAS blockade
Combining classes of agents with complementary mechanisms of action, such as CCBs and RAS blockers, provides greater BP-lowering efficacy than monotherapy, [68] [69] [70] [71] [72] [73] [74] [75] with a comparable and potentially improved adverse-event profile. 76 However, few trials have been designed to test the effect of specific antihypertensive combinations on cardiovascular or renal end points. [77] [78] [79] [80] [81] Dual RAS/CCB blockade would seem a propitious combination, since these classes of antihypertensive agents target multiple mechanisms involved in hypertensive vascular disease progression. This hypothesis is supported by the recently reported results of the JIKEI Heart Study, 82 a prospective, randomized, open-label, blinded end point (PROBE) trial of more than 3000 patients with hypertension and cardiovascular disease treated to target BP of 130/80 mm Hg. The trial was halted after approximately 3 years based on the finding that addition of the ARB valsartan to existing antihypertensive therapy, which included a CCB in approximately two-thirds of patients, resulted in a significant reduction in the primary composite end point of cardiovascular morbidity/mortality (P ¼ 0.0002) and secondary end points of stroke and hospitalization for angina (P ¼ 0.0001) and heart failure (P ¼ 0.03). In this study, comparable BP reductions were achieved (1 mm Hg difference in favour of the ARB arm). 82 
Preclinical studies
The CCB/RAS blockade combination provides cardioprotection through a variety of mechanisms, perhaps the most significant of which is enhanced NO production. CCBs and ACE inhibitors stimulate NO production through kinin-dependent mechanisms, and preclinical evidence suggests that the combination has additive effects. 83, 84 In one study, canine isolated coronary microvessels were incubated with increasing concentrations of amlodipine plus low-dose ramiprilat or increasing doses of ramiprilat plus low-dose amlodipine. Ramiprilat increased amlodipine-induced nitrite production (a hydration product of NO) by as much as 77%, while amlodipine increased ramiprilat-induced nitrite production by as much as 105%. 83 Other investigators have shown that by modulating kininmediated NO release, a CCB/ACE inhibitor combination has an additive effect in regulating myocardial oxygen consumption in normal canine and failing human hearts. 84 The neurohormonal imbalance between angiotensin II and NO associated with endothelial dysfunction also contributes to inflammation and cardiac remodelling following myocardial ischaemia. A recent study in Lewis rats with occluded left anterior descending arteries used a microdialysis technique to evaluate the effects of amlodipine, benazepril, alone and in combination, and hydrochlorothiazide on mediators of myocardial ischaemia in cardiac interstitial fluid. 58 Both amlodipine and benazepril significantly decreased levels of all inflammatory markers (tumour necrosis factor-a, interleukin-6, nuclear factor-kB) compared with untreated ischaemia, and the CCB/ ACE inhibitor combination caused a further decrease in inflammatory markers. In addition, both amlodipine and benazepril increased cardiac interstitial fluid levels of NO metabolites compared with untreated ischaemia, and the combination resulted in a further increase. Histologic examination indicated that benazepril but not amlodipine limited infarct expansion, whereas the combination attenuated infarct expansion, preserved cardiac structure and limited cell infiltration. Hydrochlorothiazide had no effect on any variable. The investigators postulated that amlodipine/benazepril combination therapy may have beneficial effects in the management of cardiac ischaemia by limiting inflammation and restoring neurohormonal balance. 58 A study of structural remodelling after myocardial infarction in dogs showed that both a CCB and an ACE inhibitor normalized the media-lumen ratio in resistance vessels of the noninfarct zone, but by different mechanisms: media thickness increased with the CCB but not with the ACE inhibitor, and transforming growth factor-b in the noninfarct zone decreased with the ACE inhibitor but not with the CCB. Normalization of the media-lumen ratio had beneficial effects on left ventricular remodelling and function. 85 Proteinuria and albuminuria are markers for renal injury and consequently increased risk of progressive renal and vascular disease. 86, 87 A recent study evaluated the effects of hydrochlorothiazide, benazepril and amlodipine as monotherapy or combination therapy on target organ injury in Dahl saltsensitive rats fed a high-salt diet and treated for 6 weeks. 88 A significant reduction in proteinuria was observed with monotherapy using each of the agents compared with control rats fed a high-salt diet, whereas combination therapy with amlodipine/benazepril or benazepril/hydrochlorothiazide normalized urinary protein excretion to levels similar to those in the normal-salt control group. In addition, combination therapy resulted in greater reductions in systolic BP, achieving levels similar to those in the normal-salt control group, and was more effective for improving endothelial function and reducing aortic and left ventricular hypertrophy. 88 The mechanisms of vascular damage in diabetic persons are complex, but endothelial dysfunction, decreased NO bioavailability and excess production of reactive oxygen species play key roles in the pathogenic process. 89 Patients with diabetes are at high risk for developing kidney disease, and both systolic and diastolic hypertension markedly accelerate the progression of diabetic nephropathy. 90 The long-term effects of amlodipine and benazepril alone and in combination were evaluated in a genetic rodent model of type II diabetes and spontaneous hypertension. 91 The low-dose combination administered for 3 months significantly lowered BP (mean systolic BP, 13272 vs 16272 mm Hg), urinary protein excretion (70.774 vs 114.7712 mg/17 h) and left ventricular weight (0.19770.004 vs 0.21970.005 g/100 g body weight) compared with no treatment. These effects were not associated with changes in renal function or plasma glucose, insulin or lipid levels. Benazepril administered alone, but not amlodipine, was associated with similar significant reductions in urinary protein excretion and left ventricular weight. The fixeddose combination was as effective as monotherapy with either drug administered at double the dose for lowering BP, proteinuria and cardiac hypertrophy without adverse metabolic effects. 91 Clinical studies Table 1 summarizes recent clinical trials that evaluated target organ effects of dual calcium channel/RAS blockade. 22, [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] Treatment with the combination of amlodipine and an ACE inhibitor or ARB improved renal function in several studies of patients with diabetic or nondiabetic kidney disease. [92] [93] [94] [95] [96] [97] [98] Combination of CCB/RAS blockade showed earlier and greater improvement in measures of renal function than monotherapy, and benefit comparable to dual RAS blockade (an ACE inhibitor plus an ARB). In the largest of these studies (N ¼ 453), conducted in patients with hypertension, type II diabetes and microalbuminuria, treatment with amlodipine, fosinopril or combination therapy significantly reduced urinary albumin excretion (UAE) over 4 years without any effect on glucose homeostasis. However, treatment with an ACE inhibitor alone or in combination produced significant improvement at 3 months versus 18 months with CCB monotherapy, and the combination reduced UAE and BP to a greater extent than monotherapy. 92 In addition, a greater percentage of patients treated with the combination were nonmicroalbuminuric at 4 years than with CCB or ACE inhibitor monotherapy (67, 33 and 46%, respectively). Although aggressive BP control is fundamental to protecting the kidney from damage owing to hypertension, investigators suggested that 92 Dose is also an important consideration. In a dose-ranging study of CCB/ARB combination therapy, a significantly greater improvement in renal function was observed with a higher versus lower dose of the ARB. 93 Combination CCB/ACE inhibitor therapy also appears to have beneficial effects on fibrinolysis in patients with diabetes. A small study in patients with hypertension and type II diabetes found that the combination of amlodipine/benazepril significantly decreased plasma PAI-1 activity (Po0.05), largely due to the ACE inhibitor, and significantly increased t-PA activity (Po0.05), largely due to the CCB component. 22 Two studies of amlodipine/ benazepril demonstrate that the combination significantly increases arterial compliance and distensibility compared with monotherapy. 98, 100 In a study of patients with mild-to-moderate hypertension, a lower-dose amlodipine/benazepril combination significantly improved arterial distensibility compared with higher doses of each drug given as monotherapy. 100 In addition, the combination significantly decreased left ventricular mass versus the CCB but not the ACE inhibitor alone. Finally, this combination has been shown to increase flowmediated vasodilation in hypertensive patients with metabolic and/or cardiovascular risk factors. 101 
Outcomes trials
Two major cardiovascular outcomes trials comparing the effects of a CCB/ACE inhibitor-based regimen with a b-blocker/diuretic-based regimen found no significant differences between treatments for cardiovascular outcomes but a lower risk of developing diabetes with CCB/ACE inhibitor-based therapy. 78, 79 The International Verapamil SR and Trandolapril Study (INVEST) 78 of more than 22 500 patients with coronary artery disease reported no significant difference between the nondihydropyridine CCB/ACE inhibitor-based and the b-blocker/ diuretic-based regimens after a mean of 2.7 years for BP reductions or the primary composite outcome of death, nonfatal myocardial infarction or nonfatal stroke; however, CCB/ACE inhibitor-based therapy was associated with a 15% lower relative risk of developing diabetes during treatment. 78 In the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), 79 19 257 patients with hypertension and at least three other cardiovascular risk factors were randomly assigned to amlodipine plus perindopril as needed versus atenolol plus bendroflumethiazide as needed to achieve BP targets. The trial was halted early at 5.5 years based on the nonsignificant reduction of major cardiovascular events with CCB/ACE inhibitor therapy versus the b-blocker/diuretic therapy (unadjusted hazard ratio, 0.9; P ¼ 0.1052). CCB/ACE inhibitor therapy was also associated with a 30% reduction in new-onset diabetes (Po0.0001). 79 ASCOT investigators found that pulse pressure best predicted cardiovascular events and speculated that the benefit conferred by the CCB-based regimen might relate to variables linked to differences in BP not measured in the trial. 80 In a substudy of ASCOT, the Conduit Artery Function Evaluation (CAFE), 102 central aortic pressure and haemodynamic variables were assessed in 2199 patients for 4 years. Both regimens produced similar reductions in brachial systolic BP (P ¼ 0.2); however, the CCB/ACE inhibitor regimen produced significantly greater reductions in central aortic systolic BP (4.3 mm Hg; 95% confidence interval: 3.3-5.4 mm Hg; Po0.0001) and central aortic pulse pressure (3.0 mm Hg; 95% confidence interval: 2.1-3.9 mm Hg; Po0.0001) than the b-blocker/diuretic regimen. Differences between brachial and central aortic BP values were consistent throughout the follow-up period. After adjustment for age and baseline risk factors, central aortic pulse pressure was significantly associated with the composite cardiovascular end point (P ¼ 0.026). 102 Although statistical superiority of CCB/ACE inhibitor combination therapy over b-blocker/diuretic regimens has not been demonstrated in large outcomes trials, clinical superiority is suggested. An ongoing trial should provide further evidence about the cardiovascular benefits of CCB/ACE inhibitor combination therapy. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial 77 compares the effects of a fixed-dose combination of amlodipine/benazepril versus benazepril plus hydrochlorothiazide in 12 600 hypertensive patients with cardiovascular risk factors, including target organ damage, kidney disease or diabetes. Unlike previous trials in which add-on therapy was based on BP response and/or presence of cardiovascular risk factors, treatment in ACCOMPLISH is initiated with the two fixed-dose combination regimens. The primary end point is a composite of cardiovascular mortality and morbidity, and results are expected in 2008. This trial will provide important information about the efficacy, safety, tolerability and clinical outcomes of a RAS blockade regimen utilizing either a CCB or a thiazide diuretic.
Conclusion
It is difficult to determine which of the beneficial effects of combination therapy with a CCB and agents that block the RAS are due to enhanced BP lowering and which are due to the ancillary effects of these agents. Nevertheless, evidence from experimental and clinical studies has shown that the complementary mechanisms of action of these antihypertensive classes provide added BP-lowering efficacy and potential renal and cardiovascular protection. Additional studies are needed to demonstrate a significant benefit on clinical outcomes with combined CCB/RAS blockade.
